Baxter and bioMérieux Announce Collaboration to Improve Identification and Treatment of Acute Kidney Injury
March 19 2019 - 1:49AM
Business Wire
Regulatory News:
Baxter International Inc. (NYSE:BAX), a global leader in acute
care, and bioMérieux (Paris:BIM), a world leader in the field of
in vitro diagnostics, announced an agreement to develop future
biomarkers with the goal to rapidly identify and inform treatment
of acute kidney injury (AKI). The announcement was made at the
International Symposium on Intensive Care and Emergency Medicine
(ISICEM) this week.
“We’re committed to improving outcomes for critically ill
patients across the continuum of care, which includes identifying
opportunities to diagnose AKI earlier so a patient can receive the
best therapy,” said Reaz Rasul, general manager of Baxter’s Acute
Therapies business. “By working with the team at bioMérieux, we’ll
be able to combine their expertise in diagnostics with our
experience in bringing the latest medical advancements to the
ICU.”
“As a leader in pioneering diagnostic solutions, we’re looking
forward to collaborating with Baxter to address the important
challenges in critical care medicine such as AKI. In order to
accomplish this, the team at the recently-acquired Astute Medical
is committed to the development of additional high medical value
biomarkers for improved patient care,” said Mark Miller, Executive
Vice President, Chief Medical Officer at bioMérieux.
AKI is a sudden decrease in kidney function over a period of
hours to days, often the result of illness, trauma or infection.
The sudden loss of kidney function leads to the accumulation of
toxins and fluid in the blood that, if left untreated, may lead to
death. The most severe stage of AKI requires renal replacement
therapy (“dialysis”) to replace the function of the kidneys. AKI is
an increasingly common complication of acute illnesses in intensive
care units and hospitals and early diagnosis is critical.1,2,3
Additional details about the agreement were not disclosed.
About bioMérieux
Pioneering Diagnostics
A world leader in the field of in vitro diagnostics for over
55 years, bioMérieux is present in 43 countries and serves
more than 160 countries with the support of a large network of
distributors. In 2018, revenues reached €2.4 billion, with
over 90% of sales outside of France.
bioMérieux provides diagnostic solutions (systems, reagents,
software, services) which determine the source of disease and
contamination to improve patient health and ensure consumer safety.
Its products are mainly used for diagnosing infectious diseases and
some critical illnesses. Its diagnostic solutions are also used for
detecting microorganisms in agri-food, pharmaceutical and cosmetic
products.
bioMérieux is listed on the Euronext Paris stock market.
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP
Corporate website: www.biomerieux.com. Investor website:
www.biomerieux-finance.com
About Baxter
Every day, millions of patients and caregivers rely on Baxter’s
leading portfolio of critical care, nutrition, renal, hospital and
surgical products. For more than 85 years, we’ve been
operating at the critical intersection where innovations that save
and sustain lives meet the healthcare providers that make it
happen. With products, technologies and therapies available in
more than 100 countries, Baxter’s employees worldwide are now
building upon the company’s rich heritage of medical breakthroughs
to advance the next generation of transformative healthcare
innovations. To learn more, visit www.baxter.com and
follow us
on Twitter, LinkedIn and Facebook.
This release includes forward-looking statements concerning the
development of AKI related biomarkers through a new collaboration
between Baxter and bioMérieux. The statements are based on
assumptions about many important factors, including the following,
which could cause actual results to differ materially from those in
the forward-looking statements: satisfaction of regulatory and
other requirements; actions of regulatory bodies and other
governmental authorities; product quality, manufacturing or supply,
or patient safety issues; changes in law and regulations; and other
risks identified in Baxter's most recent filing on Form 10-K and
other SEC filings, all of which are available on Baxter's website.
Baxter does not undertake to update its forward-looking
statements.
Baxter is a registered trademark of Baxter International
Inc.
###
1 Siew ED, Davenport A: The growth of acute kidney injury: a
rising tide or just closer attention to detail? Kidney Int
2015;87:46-61.
2 O'Connor ME, Kirwan CJ, Pearse RM, Prowle JR: Incidence and
associations of acute kidney injury after major abdominal surgery.
Intensive Care Med 2016;42:521-530.
3 Susantitaphong P, Cruz DN, Cerda J, Abulfaraj M, Alqahtani F,
Koulouridis I, Jaber BL: World incidence of AKI: a meta-analysis.
Clin J Am Soc Nephrol 2013;8:1482-1493.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190318005885/en/
Baxter Media ContactBeth Mueller, (224)
948-5353media@baxter.comBaxter Investor ContactClare Trachtman,
(224) 948-3085bioMérieux Media ContactAurore Sergeant, +334 7887
2053media@biomerieux.comTim Baker, (216)
407-5354timothy.baker@biomerieux.combioMérieux Investor
ContactSylvain Morgeau, +334 7887
5136Sylvain.morgeau@biomerieux.com
Baxter (NYSE:BAX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Baxter (NYSE:BAX)
Historical Stock Chart
From Sep 2023 to Sep 2024